eli lilly tirzepatide pill weight-loss orforglipron could get FDA approval in 2026, CEO Dave Ricks says Eli Lilly's weight-loss pill is
Description
[DOI] [Google Scholar] 55.Utzschneider K
High-risk patients may need to hold one dose based on individual assessment by their surgical and anesthesia teams
The fact that real-world results come within a few percentage points of trial data speaks to tirzepatide's robust efficacy even under imperfect conditions
Not the top of the curve
Individual results will vary
